![Andrew Hirsch](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Andrew Hirsch
Directeur Général chez
C4 THERAPEUTICS, INC.
Fortune : 597 783 $ au 31/05/2026
Profil
Andrew J.
Hirsch is President, Chief Executive Officer & Director at C4 Therapeutics, Inc. since 2020.
Mr. Hirsch is an Independent Director at Editas Medicine, Inc. since 2017.
Formerly, Mr. Hirsch was CFO & Head-Corporate Development at Agios Pharmaceuticals, Inc. from 2018 to 2020.
Mr. Hirsch was President, CEO, CAO & Director at DNIB Unwind, Inc. in 2016.
Mr. Hirsch was Chief Financial Officer at Avila Therapeutics, Inc. from 2011 to 2012.
Mr. Hirsch was VP-Corporate Strategy, Mergers & Acquisitions at Biogen, Inc. from 2002 to 2011.
Mr. Hirsch completed undergraduate studies at the University of Pennsylvania in 1992.
Mr. Hirsch earned an MBA from Tuck School of Business at Dartmouth in 1997.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
C4 THERAPEUTICS, INC. 0,12 % | 22/04/2026 | 135 209 ( 0,12 % ) | 590 863 $ | 31/05/2026 |
| 20/04/2026 | 2 000 ( 0 % ) | 6 920 $ | 31/05/2026 |
Postes actifs de Andrew Hirsch
| Sociétés | Poste | Début |
|---|---|---|
| EDITAS MEDICINE, INC. | Directeur/Membre du Conseil | 30/05/2017 |
| C4 THERAPEUTICS, INC. | Directeur Général | 02/10/2020 |
Anciens postes connus de Andrew Hirsch
| Sociétés | Poste | Fin |
|---|---|---|
| AGIOS PHARMACEUTICALS, INC. | Directeur Financier/CFO | 11/09/2020 |
| DNIB UNWIND INC | Directeur Général | 24/07/2016 |
Avila Therapeutics, Inc.
 Avila Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Researches and develops covalent drugs | Directeur Financier/CFO | 31/03/2012 |
| BIOGEN INC. | Corporate Officer/Principal | 01/06/2011 |
Formation de Andrew Hirsch
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
89
Relations au 1er degré
8
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
DNIB Unwind, Inc.
 DNIB Unwind, Inc. BiotechnologyHealth Technology Develops biopharmaceutical preparations | Health Technology |
Agios Pharmaceuticals, Inc.
 Agios Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops therapeutics | Health Technology |
University of Pennsylvania
 University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Avila Therapeutics, Inc.
Avila Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Researches and develops covalent drugs | Health Technology |
Tuck School of Business at Dartmouth
 Tuck School of Business at Dartmouth Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Editas Medicine, Inc.
 Editas Medicine, Inc. BiotechnologyHealth Technology Manufactures gene editing medicines | Health Technology |
C4 Therapeutics, Inc.
 C4 Therapeutics, Inc. BiotechnologyHealth Technology Develops targeted protein degradation therapeutics for the treatment of cancer | Health Technology |
